Episode Details

Midazolam (Versed) 80/20 Clinical Summary

• Classes: Benzodiazepine sedative/hypnotic, anesthetic, anxiolytic, anticonvulsant.
• Mechanism: Enhances GABA-A receptors, increasing GABA affinity and opening chloride channels. This hyperpolarizes cell membranes, preventing excitation. Has twice the receptor affinity of diazepam.
• Pharmacokinetics: Metabolized by CYP3A4 to active, equipotent alpha-hydroxymidazolam. 97% protein-bound. Excreted via urine.
  • IV: Onset 1.5–5m, duration 30–45m. Tissue accumulation in long infusions delays awakening.
  • IM: Onset 5m, peak 15–30m.
  • PO: Onset 10–30m, duration 40–70m, ~36% bioavailability.
  • Intranasal (Nayzilam): Bioavailability 44–55%. Nasal burning lasts ~30s.
  • Buccal/Rectal (Off-label): Onset is 10–30m; duration 40–90m.

Black Box Warning & Complications

• Boxed Warnings: Requires specialized care setting, experienced clinician, and continuous cardio-respiratory monitoring. Profound risk of respiratory depression, apnea, arrest, and hypoxic encephalopathy/death. Coadministration with opioids or other CNS depressants severely increases risks of profound sedation, respiratory depression, coma, or death.
• Adverse Effects: Respiratory depression (8–23.3%), apnea (2.8–15.4%), severe hypotension, laryngospasm, bronchospasm, bradycardia, cardiac arrest.

80/20 Clinical & Nursing Pearls

• Monitoring: Continuously monitor respiratory effort and oxygenation (pulse oximetry) to detect hypoventilation or apnea early.
• Slow IV Push: Administer over ≥2 minutes; wait ≥2 minutes to assess effects before redosing. Avoid rapid push in neonates (risk of severe hypotension, hypoventilation, seizures).
• Antidote: Flumazenil must be immediately available to reverse respiratory depression. Note: Flumazenil can precipitate life-threatening seizures in chronic benzodiazepine users.
• Gradual Taper: Do not abruptly stop after continuous use (>1–2 weeks); taper gradually to avoid acute withdrawal (seizures, status epilepticus).
• Pediatric & Neonatal Safety: Preterm neonates have significantly slower clearance. Standard infusions are not recommended for preterm neonates <32 weeks due to adverse neurological risks. Avoid benzyl alcohol-containing injectables in neonates to prevent fatal "gasping syndrome".
• Renal/Hepatic: Half-life is prolonged in renal impairment; pediatric doses must be reduced by 25% (GFR 10–29) or 50% (GFR <10). Reduced clearance occurs in hepatic impairment.
• Why Choose This Drug? Preferred for rapid-onset, short-duration procedural sedation, amnesia, and acute seizure control (drug of choice for emergent IM seizure therapy)